A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer

References

• American Cancer SocietyCancer Facts and Figures 2012Atlanta, GAAmerican Cancer Society2012 Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdfAccessed July 29, 2012
   Google Scholar
• FuJBKauTYSeversonRKKalemkerianGPLung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results databaseChest2005127376877715764756
   PubMed Web of Science ®Google Scholar
• MorgenszternDWaqarSSubramanianJGaoFGovindanRImproving survival for stage IV non-small cell lung cancer: a Surveillance, Epidemiology, and End Results survey from 1990 to 2005J Thorac Oncol20094121524152919752759
   PubMed Web of Science ®Google Scholar
• AlatorreCICarterGCChenCA comprehensive review of predictive and prognostic composite factors implicated in the heterogeneity of treatment response and outcome across disease areasInt J Clin Pract201165883184721718398
   PubMed Web of Science ®Google Scholar
• SargentDJConleyBAAllegraCColletteLClinical trial designs for predictive marker validation in cancer treatment trialsJ Clin Oncol20052392020202715774793
   PubMed Web of Science ®Google Scholar
• YipDHarperPGPredictive and prognostic factors in small cell lung cancer: current statusLung Cancer200028317318510812187
   PubMed Web of Science ®Google Scholar
• Fernandez y GarciaENguyenHDuanNGablerNBKravitzRLAssessing heterogeneity of treatment effects: are authors misinterpreting their results?Health Serv Res2010451283301
   Web of Science ®Google Scholar
• KentDMRothwellPMIoannidisJPAltmanDGHaywardRAAssessing and reporting heterogeneity in treatment effects in clinical trials: a proposalTrials2010118520704705
   PubMed Web of Science ®Google Scholar
• GablerNBDuanNLiaoDElmoreJGGaniatsTGKravitzRLDealing with heterogeneity of treatment effects: is the literature up to the challenge?Trials2009104319545379
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin– paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• MaltoniMCaraceniABrunelliCPrognostic factors in advanced cancer patients: evidence-based clinical recommendations – a study by the Steering Committee of the European Association for Palliative CareJ Clin Oncol200523256240624816135490
   PubMed Web of Science ®Google Scholar
• BrundageMDDaviesDMackillopWJPrognostic factors in non-small cell lung cancer: a decade of progressChest200212231037105712226051
   PubMed Web of Science ®Google Scholar
• SocinskiMAMorrisDEMastersGALilenbaumRChemotherapeutic management of stage IV non-small cell lung cancerChest2003123Suppl 1226S243S12527582
   PubMed Web of Science ®Google Scholar
• ComellaPGambardellaAFrasciGAvalloneACostanzoRComparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trialsCrit Rev Oncol Hematol200865216417117702595
   PubMed Web of Science ®Google Scholar
• Di MaioMLamaNMorabitoAClinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomized trialsEur J Cancer201046473574320045311
   PubMed Web of Science ®Google Scholar
• Di MaioMMorabitoABarberaSEducation level as prognostic factor of patients (pts) with advanced non-small cell lung cancer (NSCLC) enrolled in clinical trials [abstract]J Clin Oncol201028Suppl 15 abstract 6124
   Google Scholar
• HatzidakiDAgelakiSMavroudisDVlachonikolisIAlegakisAGeorgouliasVA retrospective analysis of second-line chemotherapy or best supportive care in patients with advanced-stage non-small-cell lung cancerClin Lung Cancer200681495516870046
   PubMed Web of Science ®Google Scholar
• HoangTXuRSchillerJHBonomiPJohnsonDHClinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group dataJ Clin Oncol200523117518315625371
   PubMed Web of Science ®Google Scholar
• JeremicBMilicicBDagovicAAleksandrovicJNikolicNPretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapyJ Cancer Res Clin Oncol2003129211412212669236
   PubMed Web of Science ®Google Scholar
• MaedaTUeokaHTabataMPrognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicate poor prognosisJpn J Clin Oncol2000301253454111210162
   PubMed Web of Science ®Google Scholar
• MandrekarSJSchildSEHillmanSLA prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trialsCancer2006107478179216847887
   PubMed Web of Science ®Google Scholar
• PallisAGPolyzosABoukovinasIPooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experienceJ Thorac Oncol20083550551018449003
   PubMed Web of Science ®Google Scholar
• WakeleeHABernardoPJohnsonDHSchillerJHChanges in the natural history of nonsmall cell lung cancer (NSCLC) – comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990Cancer2006106102208221716604529
   PubMed Web of Science ®Google Scholar
• Wheatley-PricePBlackhallFLeeSMThe influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trialsAnn Oncol201021102023202820332134
   PubMed Web of Science ®Google Scholar
• EfficaceFBottomleyASmitEFIs a patient’s self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975Ann Oncol200617111698170416968876
   PubMed Web of Science ®Google Scholar
• EtonDTFaircloughDLCellaDYountSEBonomiPJohnsonDHEarly change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592J Clin Oncol20032181536154312697878
   PubMed Web of Science ®Google Scholar
• MaionePPerroneFGalloCPretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly studyJ Clin Oncol200523286865687216192578
   PubMed Web of Science ®Google Scholar
• ScagliottiGVDe MarinisFRinaldiMThe role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trialJ Thorac Oncol20094121568157120009911
   PubMed Web of Science ®Google Scholar
• SederholmCHillerdalGLambergKPhase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study GroupJ Clin Oncol200523338380838816293868
   PubMed Web of Science ®Google Scholar
• TeramukaiSKitanoTKishidaYPretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organization LC00-03Eur J Cancer200945111950195819231158
   PubMed Web of Science ®Google Scholar
• WakeleeHAWangWSchillerJHSurvival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594J Thorac Oncol20061544144617409897
   PubMed Web of Science ®Google Scholar
• WeissGJRosellRFossellaFThe impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancerAnn Oncol200718345346017322539
   PubMed Web of Science ®Google Scholar
• ComellaPFrasciGCarnicelliPGemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patientsBr J Cancer200491348949715266334
   PubMed Web of Science ®Google Scholar
• GeorgouliasVAgelidouASyrigosKSecond-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomized Phase II studyBr J Cancer200593776376916175189
   PubMed Web of Science ®Google Scholar
• HanJYLimHSLeeDHRandomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinomaCancer2006106487388016411223
   PubMed Web of Science ®Google Scholar
• HelbekkmoNAaseboUSundstromSHvon PlessenCBrunsvigPFBremnesRMTreatment outcome in performance status two advanced NSCLC patients administered platinum-based combination chemotherapyLung Cancer200862225326018417246
   PubMed Web of Science ®Google Scholar
• KodaniTUeokaHKiuraKA Phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factorsLung Cancer200236331331912009244
   PubMed Web of Science ®Google Scholar
• KosmidisPMylonakisNSkarlosDPaclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG)Ann Oncol200011779980510997806
   PubMed Web of Science ®Google Scholar
• MoscettiLNelliFPadalinoDSperdutiIGiannarelliDPolleraCFGemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcomeJ Chemother200517668569216433202
   PubMed Web of Science ®Google Scholar
• NgeowJLeongSSGaoFImpact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance statusCrit Rev Oncol Hematol2010761536019939700
   PubMed Web of Science ®Google Scholar
• SculierJPLafitteJJLecomteJA three-arm Phase III randomized trial comparing combinations of platinum derivatives, ifosfamide, and/or gemcitabine in stage IV non-small-cell lung cancerAnn Oncol200213687488212123332
   PubMed Web of Science ®Google Scholar
• BischoffHGvan den BorneBPimentelFLObservation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study)Curr Med Res Opin20102661461147020394472
   PubMed Web of Science ®Google Scholar
• GirardNJacouletPGainetMThird-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practiceJ Thorac Oncol20094121544154919884862
   PubMed Web of Science ®Google Scholar
• KochAFohlinHSorensonSPrognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapyJ Thorac Oncol20094332633219155996
   PubMed Web of Science ®Google Scholar
• ParalkarVRLiTLangerCJPopulation characteristics and prognostic factors in metastatic non-small-cell lung cancer: a Fox Chase Cancer Center retrospectiveClin Lung Cancer20089211612118501099
   PubMed Web of Science ®Google Scholar
• ProvencioMCoboMVazquez-EstevezSAnalysis of prognostic factors in patients with advanced non-small cell lung cancer (NSCLC) who are candidates to receive a second-line treatment [abstract]J Clin Oncol201028suppl 15 abstract e18109
   Google Scholar
• ScartozziMMazzantiPGiampieriRClinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: selecting the unselectable?Lung Cancer201068343343719664842
   PubMed Web of Science ®Google Scholar
• TohCKWongEHLimWTThe impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysisChest200412661750175615596669
   PubMed Web of Science ®Google Scholar
• WangXSShiQLuCPrognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancerCancer2010116113714519852033
   PubMed Web of Science ®Google Scholar
• AkechiTOkamuraHOkuyamaTFurukawaTANishiwakiYUchitomiYPsychosocial factors and survival after diagnosis of inoperable non-small cell lung cancerPsychooncology2009181232918484649
   PubMed Web of Science ®Google Scholar
• ChuDTKimSWHsuHKPatient attitudes towards chemotherapy and survival: a prospective observational study in advanced non-small cell lung cancerLung Cancer200966225025619264374
   PubMed Web of Science ®Google Scholar
• ItayaTYamaotoNAndoMInfluence of histological type, smoking history, and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancerCancer Sci200798222623017233840
   PubMed Web of Science ®Google Scholar
• JacotWColinetBBertrandDQuality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patientsAnn Oncol20081981458146418356134
   PubMed Web of Science ®Google Scholar
• ShepherdFAAbrattRCrinoLThe influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancerLung Cancer200030211712511086205
   PubMed Web of Science ®Google Scholar
• SculierJPLafitteJJLecomteJA Phase III randomized trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancerAnn Oncol20071861037104217404152
   PubMed Web of Science ®Google Scholar
• KogureYAndoMChibaYImpact of histology and smoking status on survival outcome of patients with advanced non-small cell lung cancer (NSCLC): West Japan Oncology Group (WJOG) study 3906L [abstract]J Clin Oncol201028Suppl 15 abstract e18013
   Google Scholar
• QiYSchildSEMandrekarSJPretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancerJ Thorac Oncol2009491075108219546817
   PubMed Web of Science ®Google Scholar
• BerghmansTLafitteJJLecomteJSecond-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working PartyBr J Cancer200796111644164917473825
   PubMed Web of Science ®Google Scholar
• TartariRFAbreu NunesCMoreiraJThe mid-arm muscle circumference measurement and the prognosis of stage IV non-small cell lung cancer patients [abstract]J Clin Oncol201028Suppl 15 abstract e18058
   Web of Science ®Google Scholar
• LilenbaumRVillaflorVMLangerCSingle-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of two: prognostic factors and treatment selection based on two large randomized clinical trialsJ Thorac Oncol20094786987419487960
   PubMed Web of Science ®Google Scholar
• LiJChenPDaiCHLiXQBaoQLPrognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapyOncology200976535536219321963
   PubMed Web of Science ®Google Scholar
• GotoYSekineIYamadaKInfluence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patientsJ Thorac Oncol20083441241618379361
   PubMed Web of Science ®Google Scholar
• ArdizzoniABoniLTiseoMCisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysisJ Natl Cancer Inst2007991184785717551145
   PubMed Web of Science ®Google Scholar
• ObasajuCKAnsariRHSocinskiMAA comparison of white and African American outcomes from a three-arm, randomized, Phase III multicenter trial of advanced or metastatic non-small cell lung cancerJ Thorac Oncol201057993100020593535
   PubMed Web of Science ®Google Scholar
• SoriaJCBrisgandDLe ChevalierTDo all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?Ann Oncol200112121667167011843242
   PubMed Web of Science ®Google Scholar
• SyrigosKNVansteenkisteJParikhPPrognostic and predictive factors in a randomized Phase III trial comparing cisplatin–pemetrexed versus cisplatin–gemcitabine in advanced non-small-cell lung cancerAnn Oncol201021355656119828561
   PubMed Web of Science ®Google Scholar
• HirschFRSpreaficoANovelloSWoodMDSimmsLPapottiMThe prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature reviewJ Thorac Oncol20083121468148119057275
   PubMed Web of Science ®Google Scholar
• GebbiaVGalettaDDe MarinisFNon small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trialsAnn Oncol200516Suppl 4iv123iv13115923412
   PubMed Web of Science ®Google Scholar
• BerghmansTPaesmansMSculierJPPrognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic, and new biological variablesTher Adv Med Oncol20113312713821904576
   PubMedGoogle Scholar
• JemalASiegelRWardECancer statistics, 2008CA Cancer J Clin2008582719618287387
   PubMed Web of Science ®Google Scholar
• EdgeSBByrdDRComptonCCFritzAGGreeneFLTrottiAAJCC Cancer Staging Manual7th edNew York, NYSpringer2010
   Google Scholar
• ScagliottiGBrodowiczTShepherdFTreatment-by-histology interaction analyses in three Phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancerJ Thorac Oncol201161647021119545
   PubMed Web of Science ®Google Scholar
• SandlerAYiJDahlbergSTreatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancerJ Thorac Oncol2010591416142320686429
   PubMed Web of Science ®Google Scholar
• OrdituraMRomanoCDe VitaFBehavior of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survivalCancer Immunol Immunother2000491053053611129323
   PubMed Web of Science ®Google Scholar